VIE Viela Bio, Inc.

Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.

$52.98  0.00 (0.00%)
As of 03/04/2021 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
06/28/2019
54,950,149
1,183,435
$2,911,258,894
0.00%
SEC Edgar Online
10-Q
10-K
926613100
US9266131005
BKRSN18

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-59.15
-0.18
90.09
-31.72%
-398.72%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy